These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 21996981)

  • 1. Critical evaluation of rituximab rescue in 27 patients with different types of kidney disease.
    Ganzemueller J; Hartmann B; Keller F; Stracke S
    Minerva Urol Nefrol; 2011 Dec; 63(4):263-72. PubMed ID: 21996981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab is not a "magic drug" in post-transplant recurrence of nephrotic syndrome.
    Grenda R; Jarmużek W; Rubik J; Piątosa B; Prokurat S
    Eur J Pediatr; 2016 Sep; 175(9):1133-1137. PubMed ID: 27364906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined use of rituximab and plasmapheresis pre-transplant increases post-transplant infections in renal transplant recipients with basiliximab induction therapy.
    Chung BH; Yun JT; Ha SE; Kim JI; Moon IS; Choi BS; Park CW; Kim YS; Yang CW
    Transpl Infect Dis; 2013 Dec; 15(6):559-68. PubMed ID: 24011062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of ABO-incompatible kidney transplant with rituximab and double-filtration plasmapheresis.
    Han S; Hwang E; Park S; Park U; Kim H; Cho W
    Exp Clin Transplant; 2014 Oct; 12(5):401-4. PubMed ID: 25299367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil.
    Kabei K; Uchida J; Iwai T; Yamasaki T; Kuwabara N; Naganuma T; Kumada N; Nakatani T
    Transpl Immunol; 2014 Aug; 31(2):92-7. PubMed ID: 24932811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
    Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
    Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effect of rituximab in maintaining remission of recurrent and plasmapheresis-dependent nephrotic syndrome post-renal transplantation - case report.
    Grenda R; Jarmużek W; Piątosa B; Rubik J
    Pediatr Transplant; 2011 Sep; 15(6):E121-5. PubMed ID: 20331516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation.
    Tsagalis G; Psimenou E; Nakopoulou L; Laggouranis A
    Artif Organs; 2011 Apr; 35(4):420-5. PubMed ID: 20637013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in highly sensitized kidney transplant recipients.
    Munoz AS; Rioveros AA; Cabanayan-Casasola CB; Danguilan RA; Ona ET
    Transplant Proc; 2008 Sep; 40(7):2218-21. PubMed ID: 18790197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
    Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
    Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center.
    Jain AB; Marcos A; Pokharna R; Shapiro R; Fontes PA; Marsh W; Mohanka R; Fung JJ
    Transplantation; 2005 Dec; 80(12):1692-8. PubMed ID: 16378063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of rituximab treatment in children with primary glomerulonephritis.
    Zachwieja J; Silska M; Ostalska-Nowicka D; Soltysiak J; Lipkowska K; Blumczynski A; Musielak A
    J Nephrol; 2012; 25(6):1060-6. PubMed ID: 22322817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment.
    Garcia VD; Bonamigo Filho JL; Neumann J; Fogliatto L; Geiger AM; Garcia CD; Barros V; Keitel E; Bittar AE; Ferrera des Santos A; Roithmann S
    Transpl Int; 2003 Mar; 16(3):202-6. PubMed ID: 12664217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly Sensitized Patients: Miami Transplant Institute Experience.
    Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
    Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab and chronic plasmapheresis therapy of nephrotic syndrome in renal transplantation patients with recurrent focal segmental glomerulosclerosis.
    Rodríguez-Ferrero M; Ampuero J; Anaya F
    Transplant Proc; 2009; 41(6):2406-8. PubMed ID: 19715934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central nervous system lymphoproliferative disorder in pediatric kidney transplant recipients.
    Traum AZ; Rodig NM; Pilichowska ME; Somers MJ
    Pediatr Transplant; 2006 Jun; 10(4):505-12. PubMed ID: 16712612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatal late-onset Pneumocystis pneumonia after rituximab: administration for posttransplantation recurrence of focal segmental glomerulosclerosis--case report.
    Dęborska-Materkowska D; Kozińska-Przybył O; Mikaszewska-Sokolewicz M; Durlik M
    Transplant Proc; 2014 Oct; 46(8):2908-11. PubMed ID: 25380948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isoagglutinin adsorption in ABO-incompatible transplantation.
    Genberg H; Kumlien G; Wennberg L; Tydén G
    Transfus Apher Sci; 2010 Oct; 43(2):231-5. PubMed ID: 20667787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.